AstraZeneca spells out a major drop in the risk of death for stage 3 NSCLC patients taking Imfinzi — and why that's important
AstraZeneca’s top team under Pascal Soriot $AZN has spent the past 5 years proving that it could do serious blockbuster development work. And few trials …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
